{"id":4350,"date":"2025-08-19T14:31:34","date_gmt":"2025-08-19T11:31:34","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4350"},"modified":"2025-08-19T15:44:33","modified_gmt":"2025-08-19T12:44:33","slug":"itf-therapeutics-launching-a-study-to-evaluate-the-real-world-experience-of-duvyzat-givinostat-in-patients-with-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/itf-therapeutics-launching-a-study-to-evaluate-the-real-world-experience-of-duvyzat-givinostat-in-patients-with-duchenne-muscular-dystrophy\/","title":{"rendered":"ITF Therapeutics lance une \u00e9tude visant \u00e0 \u00e9valuer l&#039;exp\u00e9rience r\u00e9elle du Duvyzat (Givinostat) chez les patients atteints de dystrophie musculaire de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">L&#039;objectif de cette \u00e9tude observationnelle prospective (NCT07127978) est d&#039;\u00e9valuer la s\u00e9curit\u00e9, la tol\u00e9rance et les r\u00e9sultats fonctionnels des patients atteints de DMD qui d\u00e9butent un traitement oral par Duvyzat (Givinostat) ou qui ont d\u00e9j\u00e0 d\u00e9but\u00e9 le traitement il y a moins de six mois dans le cadre de soins cliniques standard aux \u00c9tats-Unis. Avec une p\u00e9riode de recrutement de 24 mois et un suivi d&#039;au moins deux ans, l&#039;essai devrait durer jusqu&#039;\u00e0 cinq ans pour les premiers patients recrut\u00e9s.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Apprendre encore plus<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/fr\/duvyzat-givinostat-nonsteroidal-drug\/\" target=\"_blank\" rel=\"noreferrer noopener\">Qu&#039;est-ce que Duvyzat (Givinostat) ?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&#039;\u00e9tude recrutera 300 participants (180 patients non ambulatoires et jusqu&#039;\u00e0 120 patients ambulatoires). Les participants seront suivis pendant au moins deux ans, les donn\u00e9es \u00e9tant recueillies lors de visites cliniques de routine. Les \u00e9valuations porteront sur les param\u00e8tres biologiques (par exemple, num\u00e9ration plaquettaire, triglyc\u00e9rides), les fonctions cardiaque et pulmonaire, les r\u00e9sultats rapport\u00e9s par les patients et les \u00e9chelles de fonction motrice telles que l&#039;\u00e9valuation ambulatoire North Star (NSAA) et l&#039;\u00e9chelle de performance des membres sup\u00e9rieurs (PUL).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\u00c9tude Duvyzat (Givinostat) \u2013 NCT07127978 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Cette \u00e9tude \u00e9value l\u2019exp\u00e9rience r\u00e9elle du Givinostat chez les patients atteints de dystrophie musculaire de Duchenne. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>D\u00e9but de l&#039;\u00e9tude (estim\u00e9)<\/strong>: 2025-09-15<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement du primaire (estim\u00e9) :<\/strong> 2030-06-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement de l&#039;\u00e9tude (estim\u00e9)<\/strong>: 2030-07-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nombre de participants (estim\u00e9)<\/strong>: 300<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Type d&#039;\u00e9tude<\/strong>: Observationnel<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Emplacements<\/strong>: Aucune donn\u00e9e de localisation pour le moment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c2ges admissibles aux \u00e9tudes<\/strong>: 6 ans et plus (enfant, adulte, adulte plus \u00e2g\u00e9)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Principaux crit\u00e8res d\u2019inclusion et d\u2019exclusion. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07127978\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07127978<\/a> \u2013<\/p>","protected":false},"excerpt":{"rendered":"<p>The purpose of this prospective observational study (NCT07127978) is to assess the safety, tolerability, and functional results of DMD patients who are starting oral Duvyzat (Givinostat) for the first time or who have already begun therapy within six months as part of standard clinical care in the United States. With a 24-month enrollment period and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4353,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[46,47],"class_list":["post-4350","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-duvyzat","tag-givinostat"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=4350"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4350\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/4353"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=4350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=4350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=4350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}